135
Participants
Start Date
February 28, 2013
Primary Completion Date
May 18, 2016
Study Completion Date
June 18, 2016
Docetaxel
Docetaxel given in Arm 1 prior to first progression on study. Given as an option of salvage therapy after first progression on study for Arms 2a and 2b.
HyperAcute®-Lung Immunotherapy
"HAL-1, HAL-2 and HAL-3 immunotherapy components.~Up to 16 immunizations of 300 million immunotherapy cells."
Gemcitabine
Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
Pemetrexed
Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
Richmond University Medical Center, Staten Island
Lynchburg Hematology Oncology Clinic, Lynchburg
Wake Forest Baptist Health, Winston-Salem
University of Florida, Gainesville
University of Tennessee Medical Center, Knoxville
North Mississippi Hematology and Oncology Associates at BridgePoint, Tupelo
Ohio State University Comprehensive Cancer Center, Columbus
Cleveland Clinic, Cleveland
Gabrail Cancer Center, Canton
University of Cincinnati, Cincinnati
Indiana University, Indianapolis
Indiana University Health Goshen Center for Cancer Care, Goshen
Deaconess Clinic, Evansville
University of Wisconsin, Madison
Vince Lombardi Cancer Clinic, Green Bay
Illinois Cancer Specialists, Arlington Heights
Northwestern University, Chicago
University of Chicago, Chicago
Washington University School of Medicine, St Louis
Kansas City VA Medical Center, Kansas City
University of Kansas Cancer Center, Fairway
University of Nebraska Medical Center, Omaha
St. Joseph Heritage Healthcare, Santa Rosa
Stamford Hospital, Stamford
Lead Sponsor
NewLink Genetics Corporation
INDUSTRY